Diagnostic Accuracy and Clinical Impact of [18F]FET PET in Childhood CNS tumors

Diagnostic Accuracy and Clinical Impact of [¹⁸F]FET PET in Childhood CNS tumors

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Diagnostic Accuracy and Clinical Impact of [¹⁸F]FET PET in Childhood CNS tumors. / Marner, Lisbeth; Lundemann, Michael; Sehested, Astrid; Nysom, Karsten; Borgwardt, Lise; Mathiasen, René; Wehner, Peder S; Henriksen, Otto M; Thomsen, Carsten; Skjøth-Rasmussen, Jane; Broholm, Helle; Østrup, Olga; Forman, Julie L; Højgaard, Liselotte; Law, Ian.

I: Neuro-Oncology, Bind 23, Nr. 12, 2021, s. 2107–2116.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Marner, L, Lundemann, M, Sehested, A, Nysom, K, Borgwardt, L, Mathiasen, R, Wehner, PS, Henriksen, OM, Thomsen, C, Skjøth-Rasmussen, J, Broholm, H, Østrup, O, Forman, JL, Højgaard, L & Law, I 2021, 'Diagnostic Accuracy and Clinical Impact of [¹⁸F]FET PET in Childhood CNS tumors', Neuro-Oncology, bind 23, nr. 12, s. 2107–2116. https://doi.org/10.1093/neuonc/noab096

APA

Marner, L., Lundemann, M., Sehested, A., Nysom, K., Borgwardt, L., Mathiasen, R., Wehner, P. S., Henriksen, O. M., Thomsen, C., Skjøth-Rasmussen, J., Broholm, H., Østrup, O., Forman, J. L., Højgaard, L., & Law, I. (2021). Diagnostic Accuracy and Clinical Impact of [¹⁸F]FET PET in Childhood CNS tumors. Neuro-Oncology, 23(12), 2107–2116. https://doi.org/10.1093/neuonc/noab096

Vancouver

Marner L, Lundemann M, Sehested A, Nysom K, Borgwardt L, Mathiasen R o.a. Diagnostic Accuracy and Clinical Impact of [¹⁸F]FET PET in Childhood CNS tumors. Neuro-Oncology. 2021;23(12):2107–2116. https://doi.org/10.1093/neuonc/noab096

Author

Marner, Lisbeth ; Lundemann, Michael ; Sehested, Astrid ; Nysom, Karsten ; Borgwardt, Lise ; Mathiasen, René ; Wehner, Peder S ; Henriksen, Otto M ; Thomsen, Carsten ; Skjøth-Rasmussen, Jane ; Broholm, Helle ; Østrup, Olga ; Forman, Julie L ; Højgaard, Liselotte ; Law, Ian. / Diagnostic Accuracy and Clinical Impact of [¹⁸F]FET PET in Childhood CNS tumors. I: Neuro-Oncology. 2021 ; Bind 23, Nr. 12. s. 2107–2116.

Bibtex

@article{bdff7a582f064034ad2ad3be43a2f873,

title = "Diagnostic Accuracy and Clinical Impact of [18F]FET PET in Childhood CNS tumors",

abstract = "BACKGROUND: Central nervous system (CNS) tumors cause the highest death rates among childhood cancers, and survivors frequently have severe late effects. Magnetic resonance imaging (MRI) is the imaging modality of choice, but its specificity can be challenged by treatment-induced signal changes. In adults, O-(2-[ 18F]fluoroethyl)-L-tyrosine ([ 18F]FET) PET can assist in interpreting MRI findings. We assessed the clinical impact and diagnostic accuracy of adding [ 18F]FET PET to MRI in children with CNS tumors.METHODS: A total of 169 [ 18F]FET PET scans were performed in 97 prospectively and consecutively included patients with known or suspected childhood CNS tumors. Scans were performed at primary diagnosis, before or after treatment, or at relapse.RESULTS: Adding [ 18F]FET PET to MRI impacted clinical management in 8% [95% confidence interval (CI): 4-13%] of all scans (n=151) and in 33% [CI: 17-53%] of scans deemed clinically indicated due to difficult decision-making on MRI alone (n=30). Using pathology or follow-up as reference standard, the addition of [ 18F]FET PET increased specificity (1.00 [0.82-1.00] vs. 0.48 [0.30-0.70], p=0.0001) and accuracy (0.91 [CI: 0.87-0.96] vs. 0.81 [CI: 0.75-0.89], p=0.04) in 83 treated lesions and accuracy in 58 untreated lesions (0.96 [CI:0.91-1.00] vs 0.90 [CI:0.82-0.92], p<0.001). Further, in a subset of patients (n=15) [ 18F]FET uptake correlated positively with genomic proliferation index.CONCLUSIONS: The addition of [ 18F]FET PET to MRI helped discriminate tumor from non-tumor lesions in the largest consecutive cohort of pediatric CNS tumor patients presented to date.",

author = "Lisbeth Marner and Michael Lundemann and Astrid Sehested and Karsten Nysom and Lise Borgwardt and Ren{\'e} Mathiasen and Wehner, {Peder S} and Henriksen, {Otto M} and Carsten Thomsen and Jane Skj{\o}th-Rasmussen and Helle Broholm and Olga {\O}strup and Forman, {Julie L} and Liselotte H{\o}jgaard and Ian Law",

note = "{\textcopyright} The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.",

year = "2021",

doi = "10.1093/neuonc/noab096",

language = "English",

volume = "23",

pages = "2107–2116",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "12",

}

RIS

TY - JOUR

T1 - Diagnostic Accuracy and Clinical Impact of [18F]FET PET in Childhood CNS tumors

AU - Marner, Lisbeth

AU - Lundemann, Michael

AU - Sehested, Astrid

AU - Nysom, Karsten

AU - Borgwardt, Lise

AU - Mathiasen, René

AU - Wehner, Peder S

AU - Henriksen, Otto M

AU - Thomsen, Carsten

AU - Skjøth-Rasmussen, Jane

AU - Broholm, Helle

AU - Østrup, Olga

AU - Forman, Julie L

AU - Højgaard, Liselotte

AU - Law, Ian

PY - 2021

Y1 - 2021

N2 - BACKGROUND: Central nervous system (CNS) tumors cause the highest death rates among childhood cancers, and survivors frequently have severe late effects. Magnetic resonance imaging (MRI) is the imaging modality of choice, but its specificity can be challenged by treatment-induced signal changes. In adults, O-(2-[ 18F]fluoroethyl)-L-tyrosine ([ 18F]FET) PET can assist in interpreting MRI findings. We assessed the clinical impact and diagnostic accuracy of adding [ 18F]FET PET to MRI in children with CNS tumors.METHODS: A total of 169 [ 18F]FET PET scans were performed in 97 prospectively and consecutively included patients with known or suspected childhood CNS tumors. Scans were performed at primary diagnosis, before or after treatment, or at relapse.RESULTS: Adding [ 18F]FET PET to MRI impacted clinical management in 8% [95% confidence interval (CI): 4-13%] of all scans (n=151) and in 33% [CI: 17-53%] of scans deemed clinically indicated due to difficult decision-making on MRI alone (n=30). Using pathology or follow-up as reference standard, the addition of [ 18F]FET PET increased specificity (1.00 [0.82-1.00] vs. 0.48 [0.30-0.70], p=0.0001) and accuracy (0.91 [CI: 0.87-0.96] vs. 0.81 [CI: 0.75-0.89], p=0.04) in 83 treated lesions and accuracy in 58 untreated lesions (0.96 [CI:0.91-1.00] vs 0.90 [CI:0.82-0.92], p<0.001). Further, in a subset of patients (n=15) [ 18F]FET uptake correlated positively with genomic proliferation index.CONCLUSIONS: The addition of [ 18F]FET PET to MRI helped discriminate tumor from non-tumor lesions in the largest consecutive cohort of pediatric CNS tumor patients presented to date.

AB - BACKGROUND: Central nervous system (CNS) tumors cause the highest death rates among childhood cancers, and survivors frequently have severe late effects. Magnetic resonance imaging (MRI) is the imaging modality of choice, but its specificity can be challenged by treatment-induced signal changes. In adults, O-(2-[ 18F]fluoroethyl)-L-tyrosine ([ 18F]FET) PET can assist in interpreting MRI findings. We assessed the clinical impact and diagnostic accuracy of adding [ 18F]FET PET to MRI in children with CNS tumors.METHODS: A total of 169 [ 18F]FET PET scans were performed in 97 prospectively and consecutively included patients with known or suspected childhood CNS tumors. Scans were performed at primary diagnosis, before or after treatment, or at relapse.RESULTS: Adding [ 18F]FET PET to MRI impacted clinical management in 8% [95% confidence interval (CI): 4-13%] of all scans (n=151) and in 33% [CI: 17-53%] of scans deemed clinically indicated due to difficult decision-making on MRI alone (n=30). Using pathology or follow-up as reference standard, the addition of [ 18F]FET PET increased specificity (1.00 [0.82-1.00] vs. 0.48 [0.30-0.70], p=0.0001) and accuracy (0.91 [CI: 0.87-0.96] vs. 0.81 [CI: 0.75-0.89], p=0.04) in 83 treated lesions and accuracy in 58 untreated lesions (0.96 [CI:0.91-1.00] vs 0.90 [CI:0.82-0.92], p<0.001). Further, in a subset of patients (n=15) [ 18F]FET uptake correlated positively with genomic proliferation index.CONCLUSIONS: The addition of [ 18F]FET PET to MRI helped discriminate tumor from non-tumor lesions in the largest consecutive cohort of pediatric CNS tumor patients presented to date.

U2 - 10.1093/neuonc/noab096

DO - 10.1093/neuonc/noab096

M3 - Journal article

C2 - 33864083

VL - 23

SP - 2107

EP - 2116

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 12

ER -

ID: 271687623